Inactive Instrument

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

End-of-day quote Australian S.E.
- - Intraday chart for Zenyth Therapeutics Limited
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2011-02-28
Corporate Officer/Principal - 2011-02-28
Director TitleAgeSince
Director/Board Member - 2011-02-28
Director/Board Member 70 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+6.82%+24.62%-6.24% 70.73B
+0.28%+3.12%+35.58%+211.60% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
+7.15%+5.51%-52.67%-51.99% 39.94B
+1.52%+5.72%+63.45%-22.63% 30.36B
-0.82%+10.67%+65.61%+101.10% 25.96B
-0.72%-5.73%+67.62%-53.47% 22.14B
-0.22%-2.66%-4.47%+145.08% 19.96B
-0.67%+2.19%+82.36%+141.27% 16.77B
Average +0.26%+2.00%+36.67%+56.96% 36.6B
Weighted average by Cap. +0.29%+2.52%+31.41%+52.65%
Logo Zenyth Therapeutics Limited
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.
Employees
-